You are here

In the Pipeline

CDR1-based peptide derived from a human anti-DNA antibody. The peptide was shown to have a good safety profile. Clinical trial for systemic lupus erythematosus (SLE), are available.Read more >
Recombinant copper-zinc Superoxide dismutase – (CuZnSOD) for prevention of pulmonary damage in neonates, licensed to Bio-Technology General, Inc., a subsidiary of Ferring Inc. The company completed a phase II clinical trial on use of CuZnSOD in treatment of bronchopulmonary dysplasia.Read more >